[1]贾秀鹏,蒙伶俐,李海莉,等.三阴性乳腺癌与非三阴性乳腺癌组织中PD-1、PD-L1、FOXP3的差异表达及其临床意义[J].医学信息,2021,34(21):7-11.[doi:10.3969/j.issn.1006-1959.2021.21.002]
　JIA Xiu-peng,MENG Ling-li,LI Hai-li,et al.Differential Expression and Clinical Significance of PD-1, PD-L1 and FOXP3 in Triple-negative Breast Cancer and Non-triple-negative Breast Cancer Tissues[J].Medical Information,2021,34(21):7-11.[doi:10.3969/j.issn.1006-1959.2021.21.002]
点击复制

三阴性乳腺癌与非三阴性乳腺癌组织中PD-1、PD-L1、FOXP3的差异表达及其临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年21期
页码:
7-11
栏目:
出版日期:
2021-11-01

文章信息/Info

Title:
Differential Expression and Clinical Significance of PD-1, PD-L1 and FOXP3 in Triple-negative Breast Cancer and Non-triple-negative Breast Cancer Tissues
文章编号:
1006-1959（2021）21-0007-05
作者:
贾秀鹏; 蒙伶俐; 李海莉; 等
（宁波市临床病理诊断中心，浙江 宁波 315000）
Author(s):
JIA Xiu-peng; MENG Ling-li; LI Hai-li; et al.
(Ningbo Clinical Pathological Diagnosis Center,Ningbo 315000,Zhejiang,China)
关键词:
三阴性乳腺癌; 程序性死亡分子-1; 程序性死亡分子配体-1; 叉状头/翅膀状螺旋转录因子
Keywords:
Triple-negative breast cancer; programmed death molecule-1; programmed death molecule ligand-1; Forkhead/wing helix transcription factor
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2021.21.002
文献标志码:
A
摘要:
目的 探讨三阴性乳腺癌患者组织中程序性死亡分子-1（PD-1）、程序性死亡分子配体-1（PD-L1）、叉状头/翅膀状螺旋转录因子（FOXP3）的表达及其临床意义。方法 选取2015年1月-2020年1月我中心诊断的70例三阴性乳腺癌，30例非三阴性乳腺癌患者为研究对象，采用免疫组化法测定三者中PD-1、PD-L1、FOXP3表达情况，分析三阴性乳腺癌与非三阴性乳腺癌组织中PD-1、PD-L1、FOXP3的差异表达及与患者临床特征的相关性。结果 三阴性乳腺癌中PD-1、PD-L1、调节性T淋巴细胞FOXP3阳性表达率均高于非三阴性乳腺癌（P＜0.05）；三阴性乳腺癌组织中PD-1、PD-L1阳性表达率与患者年龄、肿瘤直径无显著关联性（P＞0.05）；Ⅲ级、淋巴脉管侵犯及淋巴结转移患者三阴性乳腺癌组织中PD-1、PD-L1阳性表达率分别高于Ⅰ、Ⅱ级、无淋巴血管侵犯及无淋巴结转移患者（P＜0.05）；三阴性乳腺癌组织中FOXP3阳性表达率与患者年龄、肿瘤直径、有无淋巴结转移无显著关联性（P＞0.05）；Ⅲ级及淋巴血管侵犯患者三阴性乳腺癌组织中调节性T淋巴细胞FOXP3阳性表达率分别高于Ⅰ、Ⅱ级、无淋巴血管侵犯患者（P＜0.05）。结论 三阴性乳腺癌患者癌组织中存在PD-1、PD-L1、调节性T淋巴细胞FOXP3的高表达，且其表达水平与高组织学级别、转移密切相关。
Abstract:
Objective To investigate the expression and clinical significance of programmed death molecule-1 (PD-1), programmed death molecule ligand-1 (PD-L1) and forkhead/winged helix transcription factor (FOXP3) in tissues of patients with triple-negative breast cancer.Methods A total of 70 patients of triple-negative breast cancer and 30 patients of non-triple-negative breast cancer diagnosed in our center from January 2015 to January 2020 were selected as the research objects. The expressions of PD-1, PD-L1 and FOXP3 in the three groups were determined by immunohistochemical method. The differential expressions of PD-1, PD-L1 and FOXP3 in triple-negative breast cancer and non-triple-negative breast cancer tissues and their correlation with the clinical characteristics of patients were analyzed.Results The positive expression rates of PD-1, PD-L1, regulatory T lymphocyte FOXP3 in triple-negative breast cancer were higher than those in non-triple-negative breast cancer (P<0.05). The positive expression rates of PD-1 and PD-L1 in triple-negative breast cancer tissues were not significantly correlated with patient age, tumor diameter (P>0.05).The positive expression rates of PD-1 and PD-L1 in triple-negative breast cancer tissues of patients with grade Ⅲ, lymphatic vessel invasion and lymph node metastasis were higher than those in patients with grade Ⅰ, grade Ⅱ, without lymphatic vessel invasion and without lymph node metastasis (P<0.05). There was no significant correlation between FOXP3 positive expression rate in triple-negative breast cancer tissue and patient age, tumor diameter, lymph node metastasis (P>0.05).The FOXP3 positive expression rates of regulatory T lymphocytes in triple-negative breast cancer tissues of patients with grade Ⅲ and lymphatic vessel invasion were higher than those in patients with grade Ⅰ, grade Ⅱ and without lymphatic vessel invasion (P<0.05).Conclusion PD-1, PD-L1 and FOXP3 are highly expressed in triple negative breast cancer tissues, and their expression levels are closely related to high histological grade and metastasis.

参考文献/References:

[1]Mittendorf EA,Philips AV,Meric-Bernstam F,et al.PD-L1 expression in triple-negative breast cancer[J].Cancer Immunol Res,2014,2(4):361-370.[2]Kurozumi S,Fujii T,Matsumoto H,et al.Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer[J].Med Mol Morphol,2017,50(4):185-194.[3]Schutz F,Stefanovic S,Mayer L,et al.PD-1/PD-L1 Pathway in Breast Cancer[J].Oncol Res Treat,2017,40(5):294-297.[4]Hossain DM,Panda AK,Manna A,et al.FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells[J].Immunity,2013,39(6):1057-1069．[5]隋启海,詹成,马可,等.食管鳞状细胞癌(ESCC)中PD-1/PD-L1/PD-L2的表达与临床因素及预后的相关性[J].复旦学报(医学版),2020,47(1):76-82,100.[6]吴菡,吴健,石永利,等.非小细胞肺癌组织中PD-1/PD-L1的表达及临床意义[J].临床肿瘤学杂志,2019,24(3):218-221.[7]Allison KH,Hammond MEH,Dowsett M,et al.Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update[J].J Clin Oncol,2020,38(12):1346-1366.[8]刘月平,步宏,杨文涛.2019版中国乳腺癌HER2检测指南更新解读[J].中华病理学杂志,2019,48(3):182-185.[9]Adams S,Loi S,Toppmeyer D,et al.Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study[J].Ann Oncol,2019,30(3):405-411.[10]Mavratzas A,Seitz J,Smetanay K,et al.Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer[J].Future Oncol,2020,16(3):4439-4453.[11]Jacobs JF,Idema AJ,Bol KF,et al.Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors[J].Neuro Oncol,2009,11(4):394-402.[12]Heimes AS,Schmidt M.Atezolizumab for the treatment of triple-negative breast cancer[J].Expert Opin Investig Drugs,2019,28(1):1-5.[13]Wang X,Liu Y.PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer[J].Pathol Res Pract,2020,216(3):152802. [14]Yeong J,Tan T,Chow ZL,et al.Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC[J].J Clin Pathol,2020,73(9):557-562.[15]Goschl L,Scheinecker C,Bonelli M.Treg cells in autoimmunity: from identification to Treg-based therapies[J].Semin Immunopathol,2019,41(3):301-314.[16]Qian BZ,Pollard JW.Macrophage diversity enhances tumor progression and metastasis[J].Cell,2010,141(1):39-51．[17]Hua D,Sun J,Mao Y,et al.B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma[J].Wold J Gastroenterol,2012,18(9):971-978.[18]Hou J,Yu Z,Xiang R,et al.Correlation between infiltration of FOXP3 regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer[J].Exp Mol Pathol,2014,96(3):284-291．[19]苏伟.FOXP3、COX2在结肠癌组织中的表达水平及意义[J].河北医药,2019,41(22):3371-3375.[20]Zhang H,Zhang S.The expression of Foxp3 and TLR4 in cervical cancer: association with immune escape and clinical pathology[J].Arch Gynecol Obstet,2017,295(3):705-712.[21]Zhang L,Wang XI,Ding J,et al.The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer[J].Ann Diagn Pathol,2019(40):143-151.

相似文献/References:

[1]徐忆芳,罗秀丽.基于数据挖掘的罗秀丽教授治疗三阴性乳腺癌的临床经验研究[J].医学信息,2019,32(20):159.[doi:10.3969/j.issn.1006-1959.2019.20.050]
　XU Yi-fang,LUO Xiu-li.Professor Luo Xiuli's Clinical Experience in Treating Triple-negative Breast Cancer Based on Data Mining[J].Medical Information,2019,32(21):159.[doi:10.3969/j.issn.1006-1959.2019.20.050]
[2]涂 强.lncRNAs在三阴性乳腺癌发生发展中的作用[J].医学信息,2020,33(10):37.[doi:10.3969/j.issn.1006-1959.2020.10.011]
　TU Qiang.The Role of lncRNAs in the Development of Triple Negative Breast Cancer[J].Medical Information,2020,33(21):37.[doi:10.3969/j.issn.1006-1959.2020.10.011]
[3]石少庆,宋丽丽.紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗效果及对患者病理变化的影响[J].医学信息,2023,36(02):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]
　SHI Shao-qing,SONG Li-li.The Therapeutic Effect of Paclitaxel Combined with Carboplatin in Neoadjuvant Chemotherapy for Triple Negative Breast Cancer and its Effect on Pathological Changes[J].Medical Information,2023,36(21):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]
[4]杨 洁,廖 萍,黄志平,等.二维超声及弹性成像预测三阴性乳腺癌新辅助化疗效果的价值[J].医学信息,2021,34(13):173.[doi:10.3969/j.issn.1006-1959.2021.13.048]
　YANG Jie,LIAO Ping,HUANG Zhi-ping,et al.The Value of Two-dimensional Ultrasound and Elastography in Predicting the Effect of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer[J].Medical Information,2021,34(21):173.[doi:10.3969/j.issn.1006-1959.2021.13.048]
[5]章海斌,王 练.基于糖酵解相关基因GFUS对三阴性乳腺癌疗效预测模型构建与验证[J].医学信息,2024,37(01):22.[doi:10.3969/j.issn.1006-1959.2024.01.004]
　ZHANG Hai-bin,WANG Lian.Construction and Validation of a Prediction Model for the Efficacy of Triple-negative Breast Cancer Based on the Glycolysis-related Gene GFUS[J].Medical Information,2024,37(21):22.[doi:10.3969/j.issn.1006-1959.2024.01.004]

更新日期/Last Update: 1900-01-01